All Stories

  1. Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non‐alcoholic steatohepatitis
  2. Assessment of exposure to Di (2-ethylhexyl) phthalate (DEHP) metabolites and Bisphenol A (BPA) and its importance for the prevention of cardiometabolic diseases
  3. Disparity-filtered differential correlation network analysis: a case study on CRC metabolomics
  4. Italian Children Exposure to Bisphenol A: Biomonitoring Data from the LIFE PERSUADED Project
  5. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
  6. New Insights on the Interactions Between Insulin Clearance and the Main Glucose Homeostasis Mechanisms
  7. PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
  8. Changes in Plasma Bioactive Lipids and Inflammatory Markers during a Half-Marathon in Trained Athletes
  9. Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
  10. Toxicological Assessment of Oral Co-Exposure to Bisphenol A (BPA) and Bis(2-ethylhexyl) Phthalate (DEHP) in Juvenile Rats at Environmentally Relevant Dose Levels: Evaluation of the Synergic, Additive or Antagonistic Effects
  11. Liver-targeting drugs and their effect on blood glucose and hepatic lipids
  12. External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study
  13. Krill Oil Supplementation Reduces Exacerbated Hepatic Steatosis Induced by Thermoneutral Housing in Mice with Diet-Induced Obesity
  14. SGLT2 inhibitors and thiazide enhance excretion of DEHP toxic metabolites in subjects with type 2 diabetes: A randomized clinical trial
  15. Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
  16. Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P
  17. Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance
  18. COVID-19 Infection Pandemic: From the Frontline in Italy
  19. Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects
  20. Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase
  21. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
  22. Mechanisms for increased risk of diabetes in chronic liver diseases
  23. The PNPLA3‐I148M variant increases polyunsaturated triglycerides in human adipose tissue
  24. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion
  25. Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease
  26. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
  27. Inflammatory Biomarkers are Correlated with Some Forms of Regressive Autism Spectrum Disorder
  28. Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas
  29. Association of serum lipids with β-cell function in obese children and adolescents
  30. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
  31. Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus
  32. The imprinted gene Delta like non-canonical notch ligand 1 (Dlk1) associates with obesity and triggers insulin resistance through inhibition of skeletal muscle glucose uptake
  33. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD
  34. Insulin resistance, liver inflammation and fibrosis in patients with NAFLD
  35. Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis
  36. Bile acid changes after metabolic surgery are linked to improvement in insulin sensitivity
  37. 155-LB: The Increase in Endogenous Glucose Production with SGLT2 Inhibition Is Unchanged by Renal Denervation but Highly Correlates to Urinary Glucose Excretion
  38. 1888-P: Impaired Insulin Clearance Relates to Increased Liver Fat Content in Recent-Onset Type 2 Diabetes and to Impaired Glucose Control in Recent-Onset Type 1 Diabetes
  39. 245-OR: Glucose Production and Utilization following Oral Glucose Load in Type 2 Diabetes Patients Treated with Dapagliflozin Alone and in Saxagliptin Combination
  40. Osteoprotegerin as optimal target for the screening of patients with hepatocellular carcinoma at higher risk of mortality
  41. Reduced insulin clearance relates to increased liver fat content in recent-onset type 2 diabetes and to impaired glucose control in recent-onset type 1 diabetes
  42. FRI-283-Impact on NAFLD of long-term weight loss after bariatric surgery
  43. PS-006-MBOAT7 downregulation induces hepatic lipid accumulation
  44. SAT-290-Association of liver inflammation and fibrosis score with noninvasive biomarkers in non-alcoholic fatty liver disease: Preliminary results from the MAST4HEALTH study
  45. SAT-323-Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease
  46. Role of vagal activation in postprandial glucose metabolism after gastric bypass in individuals with and without hypoglycaemia
  47. Beta-cell sensitivity to insulinotropic gut hormones is reduced after gastric bypass surgery
  48. Women-specific predictors of cardiovascular disease risk - new paradigms
  49. Metabolomic profile of morbidly obese NAFLD: effect of weight loss by exenatide or diet
  50. Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease
  51. Effects of intravenous AICAR (5-aminoimidazole-4-carboximide riboside) administration on insulin signaling and resistance in premature baboons, Papio sp.
  52. Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study
  53. Phthalates exposure as determinant of albuminuria in type 2 diabetes subjects: a cross-sectional study
  54. Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans
  55. The LIFE PERSUADED project approach on phthalates and bisphenol A biomonitoring in Italian mother-child pairs linking exposure and juvenile diseases
  56. Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars
  57. Publisher Correction: Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery
  58. Beneficial Effects of RYGB on ß-Cell Function and Hepatic and Peripheral Insulin Sensitivity Are Maintained Seven Years after Surgery in Both Diabetic and Nondiabetic Subjects
  59. Lean Subjects with Fatty Liver Show Decreased GLP-1 and GIP Response during OGTT
  60. Older Subjects With β-Cell Dysfunction Have an Accentuated Incretin Release
  61. Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research
  62. Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study
  63. Reply
  64. The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF
  65. Beta-cell sensitivity to glucose is impaired after gastric bypass surgery
  66. Author Correction: Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
  67. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance
  68. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
  69. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up
  70. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
  71. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
  72. Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery
  73. Correction
  74. The color of fat and its central role in the development and progression of metabolic diseases
  75. Glucose kinetics
  76. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study
  77. An extended fatty liver index to predict non-alcoholic fatty liver disease
  78. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
  79. Response to Comment on Gastaldelli et al. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care 2016;39:1925–1931
  80. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies
  81. Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes
  82. Increased FNDC5/Irisin expression in human hepatocellular carcinoma
  83. Hepatic Insulin Resistance and Altered Gluconeogenic Pathway in Premature Baboons
  84. Chronic Intranasal Insulin Does Not Affect Hepatic Lipids but Lowers Circulating BCAAs in Healthy Male Subjects
  85. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients
  86. Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study
  87. Response to: Drug therapy for ectopic fat: myth or reality?
  88. Pathophysiology of Non Alcoholic Fatty Liver Disease
  89. Ectopic fat: a target for cardiometabolic risk management
  90. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
  91. Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
  92. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass
  93. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
  94. Ghrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1
  95. Glucose uptake saturation explains glucose kinetics profiles measured by different tests
  96. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
  97. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
  98. Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease
  99. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial
  100. Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
  101. Early effect of Roux-en-Y gastric bypass on insulin sensitivity and signaling
  102. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease
  103. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
  104. Brown versus white fat: are they really playing a role in obesity and cardiometabolic risk?
  105. Obesity and carotid artery remodeling
  106. Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146TCF7L2Gene Variant
  107. Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System
  108. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
  109. Peripheral Insulin Resistance and Impaired Insulin Signaling Contribute to Abnormal Glucose Metabolism in Preterm Baboons
  110. The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal musclein vivo
  111. Not all fats are created equal: adipose vs. ectopic fat, implication in cardiometabolic diseases
  112. Neurophysiological and Behavioural Variables in Cognitive Impairment: Towards a Personalised Monitoring System
  113. Corrigendum to “Insulin resistance, adipose depots and gut: Interactions and pathological implications” [Dig. Liver Dis. 42 (2010) 310–319]
  114. Risk Relationship between Insulin Resistance, Diabetes, and Atherosclerotic Cardiovascular Disease
  115. The Disposition Index Does Not Reflect β-Cell Function in IGT Subjects Treated With Pioglitazone
  116. The good and bad effects of statins on insulin sensitivity and secretion
  117. Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study
  118. Pathophysiology of Prediabetes: Role of Lipotoxicity?
  119. Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women
  120. Altered Islet Function and Insulin Clearance Cause Hyperinsulinemia in Gastric Bypass Patients With Symptoms of Postprandial Hypoglycemia
  121. Matched weight loss induced by sleeve gastrectomy or gastric bypass similarly improves metabolic function in obese subjects
  122. HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
  123. Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion
  124. Comparison of Liver Fat Indices for the Diagnosis of Hepatic Steatosis and Insulin Resistance
  125. Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW
  126. Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic
  127. Blockade of Glucagon-like Peptide 1 Receptor Corrects Postprandial Hypoglycemia After Gastric Bypass
  128. Visceral Adipose Tissue and Ectopic Fat Deposition
  129. Motor Activity in Aging: An Integrated Approach for Better Quality of Life
  130. Albiglutide for the treatment of type 2 diabetes mellitus
  131. Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk
  132. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes
  133. Metabolic Consequences of Adipose Triglyceride Lipase Deficiency in Humans: An In Vivo Study in Patients With Neutral Lipid Storage Disease With Myopathy
  134. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment
  135. Increased carotid intima-media thickness in the physiologic range is associated with impaired postprandial glucose metabolism, insulin resistance and beta cell dysfunction
  136. Ectopic fat: the true culprit linking obesity and cardiovascular disease?
  137. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT
  138. Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates
  139. Long-Term Effects of Bariatric Surgery on Meal Disposal and  -Cell Function in Diabetic and Nondiabetic Patients
  140. Biliopancreatic Diversion in Nonobese Patients With Type 2 Diabetes: Impact and Mechanisms
  141. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3–TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study
  142. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
  143. The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes
  144. Imaging cardiac fat
  145. Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver
  146. Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
  147. Validation of [18F]fluorodeoxyglucose and positron emission tomography (PET) for the measurement of intestinal metabolism in pigs, and evidence of intestinal insulin resistance in patients with morbid obesity
  148. Metabolic response to high-carbohydrate and low-carbohydrate meals in a nonhuman primate model
  149. Gastric bypass and banding equally improve insulin sensitivity and β cell function
  150. The role of cardiac fat in insulin resistance
  151. Direct effect of GLP-1 infusion on endogenous glucose production in humans
  152. Hepatic and Cardiac Steatosis
  153. Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes
  154. Effects of Adding Exercise to a 16-Week Very Low-Calorie Diet in Obese, Insulin-Dependent Type 2 Diabetes Mellitus Patients
  155. The ontogeny of the endocrine pancreas in the fetal/newborn baboon
  156. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques
  157. Impact of increased visceral and cardiac fat on cardiometabolic risk and disease
  158. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease
  159. Estimation of prehepatic insulin secretion: comparison between standardized C-peptide and insulin kinetic models
  160. Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease
  161. Fatty Liver Index Predicts Further Metabolic Deteriorations in Women with Previous Gestational Diabetes
  162. Relationship between fatty liver and glucose metabolism: A cross-sectional study in 571 obese children
  163. Diabetes and Nonalcoholic Fatty Liver Disease
  164. Diet and Exercise in the Treatment of Fatty Liver
  165. Coordinated Defects in Hepatic Long Chain Fatty Acid Metabolism and Triglyceride Accumulation Contribute to Insulin Resistance in Non-Human Primates
  166. Pericardial Rather Than Epicardial Fat is a Cardiometabolic Risk Marker: An MRI vs Echo Study
  167. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population
  168. Metabolic effects of muraglitazar in type 2 diabetic subjects
  169. Ectopic Fat Storage, Insulin Resistance, and Hypertension
  170. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus
  171. Protective role of adiponectin on endothelial dysfunction induced by AGEs: A clinical and experimental approach
  172. Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects
  173. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes
  174. What is the role of the receptor for advanced glycation end products-ligand axis in liver injury?
  175. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans
  176. Liver Enzymes Are Associated With Hepatic Insulin Resistance, Insulin Secretion, and Glucagon Concentration in Healthy Men and Women
  177. Pathophysiology of Prediabetes
  178. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
  179. Mechanism and Effects of Glucose Absorption during an Oral Glucose Tolerance Test Among Females and Males
  180. Ectopic fat and cardiovascular disease: What is the link?
  181. Effect of Oral Sebacic Acid on Postprandial Glycemia, Insulinemia, and Glucose Rate of Appearance in Type 2 Diabetes
  182. ORIGINAL ARTICLE: Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study
  183. Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk
  184. Metabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trial
  185. Pioglitazone in the treatment of NASH: the role of adiponectin
  186. Fatty liver disease: the hepatic manifestation of metabolic syndrome
  187. Insulin resistance, adipose depots and gut: Interactions and pathological implications
  188. Acute effects of gastric bypass versus gastric restrictive surgery on β-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes
  189. A new approach to study in vivo cellular metabolism using a modellistic analysis of magnetic resonance spectra
  190. Pancreatic islet amyloidosis, β-cell apoptosis, and α-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons
  191. Reply:
  192. Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms
  193. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis
  194. Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study
  195. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients
  196. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C
  197. Imaging and Laboratory Biomarkers in Cardiovascular Disease
  198. The Effect of Menopause on Carotid Artery Remodeling, Insulin Sensitivity, and Plasma Adiponectin in Healthy Women
  199. Accurate segmentation of subcutaneous and intermuscular adipose tissue from MR images of the thigh
  200. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice
  201. Hepatic fat is not associated with β-cell function or postprandial free fatty acid response
  202. Heme Oxygenase-1 Induction Remodels Adipose Tissue and Improves Insulin Sensitivity in Obesity-Induced Diabetic Rats
  203. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population
  204. Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons.
  205. The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention
  206. Elevated Concentrations of Liver Enzymes and Ferritin Identify a New Phenotype of Insulin Resistance: Effect of Weight Loss After Gastric Banding
  207. Automatic correction of intensity inhomogeneities improves unsupervised assessment of abdominal fat by MRI
  208. Abdominal fat: does it predict the development of type 2 diabetes?
  209. Intra-abdominal adiposity, abdominal obesity, and cardiometabolic risk
  210. Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test
  211. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis
  212. Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects
  213. Early Hypertension Is Associated With Reduced Regional Cardiac Function, Insulin Resistance, Epicardial, and Visceral Fat
  214. Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients
  215. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach
  216. Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients
  217. Effect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women
  218. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy
  219. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
  220. Insulin Resistance, Insulin Response, and Obesity as Indicators of Metabolic Risk
  221. Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects
  222. Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training
  223. Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus
  224. Effect of Pioglitazone on the Metabolic and Hormonal Response to a Mixed Meal in Type II Diabetes
  225. Quantification of Liver Glucose Metabolism by Positron Emission Tomography: Validation Study in Pigs
  226. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes
  227. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
  228. Circulating Soluble Receptor for Advanced Glycation End Products Is Inversely Associated with Glycemic Control and S100A12 Protein
  229. Comparison of Glargine Insulin Versus Rosiglitazone Addition in Poorly Controlled Type 2 Diabetic Patients on Metformin Plus Sulfonylurea
  230. Thiazolidinediones improve beta-cell function in type 2 diabetic patients
  231. The Effect of Pioglitazone on the Liver: Role of adiponectin
  232. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome
  233. [11C]palmitate kinetics across the splanchnic bed in arterial, portal and hepatic venous plasma during fasting and euglycemic hyperinsulinemia
  234. The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
  235. Pathogenesis and Clinical Features of Obesity and Insulin Resistance
  237. Visceral fat and beta cell function in non-diabetic humans
  238.  -Cell Function in Morbidly Obese Subjects During Free Living: Long-Term Effects of Weight Loss
  239. Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity
  240.  -Cell Function in Mild Type 2 Diabetic Patients: Effects of 6-month glucose lowering with nateglinide
  241. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
  242. β-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis
  243. Beta-Cell Function in Obesity: Effects of Weight Loss
  244. Characterization of  -cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests
  245. re: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47:31?39
  246. Reply to Comment on: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 43:31?39
  247. Separate Contribution of Diabetes, Total Fat Mass, and Fat Topography to Glucose Production, Gluconeogenesis, and Glycogenolysis
  248. Visceral Fat in Hypertension: Influence on Insulin Resistance and  -Cell Function
  249. Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes
  250. An accurate and robust method for unsupervised assessment of abdominal fat by MRI
  251. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
  252. A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes
  253. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance
  254. Influence of Ethnicity and Familial Diabetes on Glucose Tolerance and Insulin Action: A Physiological Analysis
  255. Metabolic Effects of Visceral Fat Accumulation in Type 2 Diabetes
  256. Assessing Insulin Secretion by Modeling in Multiple-Meal Tests: Role of Potentiation
  257. Effect of Acute Hyperglycemia on Insulin Secretion in Humans
  258. Determination of the Enrichment of the Hydrogen Bound to Carbon 5 of Glucose on 2H2O Administration
  259. A model for assessing insulin secretion and its control under free-living conditions
  260. Insulin prolongs the QTc interval in humans
  261. Determinants of postabsorptive endogenous glucose output in non-diabetic subjects
  262. Dose-response characteristics of insulin action on glucose metabolism: a non-steady-state approach
  263. Fat metabolism during high-intensity exercise in endurance-trained and untrained men
  264. Modelling Interpretation of the Kinetics of Metabolic Processes
  265. Assessment of methods for improving tracer estimation of non-steady-state rate of appearance
  266. Insulin: new roles for an ancient hormone
  267. Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency
  268. Linear and Nonlinear Properties of Heart Rate Variability: Influence of Obesity
  269. Splanchnic and leg substrate exchange after ingestion of a natural mixed meal in humans
  270. Autonomic and Hemodynamic Responses to Insulin in Lean and Obese Humans
  271. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes
  272. Energy expenditure of swimmers during high volume training
  273. Kinetic Analysis and Comparison of Models of Xylose Metabolism byKlebsiella planticola
  274. Modeling Interpretation of Microbe Metabolism Detected by Nuclear Magnetic Resonance
  275. Effect of theophylline on substrate metabolism during exercise
  276. Lipid and carbohydrate metabolism in IDDM during moderate and intense exercise
  277. Lipid and Carbohydrate Metabolism in IDDM During Moderate and Intense Exercise
  278. Pathway of free fatty acid oxidation in human subjects. Implications for tracer studies.
  280. A Leg Model of Amino Acid Kinetics in Skin and Muscle
  281. Changes in Tracer Infusion Rates to Minimize the Structure Error in the Steele’s Model
  282. An Energy Model for the Description of a Metabolic Process
  283. Pathway of Free Fatty Acid Oxidation